At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 138 enrolled
Drug / intervention
CP-751,871drug
Likely dose
CP-751,871 30 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1/Phase 2 Study Of CP-751,871 In Patients With Relapsed And/Or Refractory Ewing's Sarcoma Family Of Tumors
In Brief
A Phase 2 clinical trial evaluating CP-751,871 for Ewing's Sarcoma Family of Tumors. Completed, enrolled 138 participants across 37 sites in 11 countries.
Detailed Summary
Define the efficacy of CP-751,871 in patients with Ewing's sarcoma family of tumors
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEwing's Sarcoma Family of Tumors
CountriesAustralia, Brazil, Canada, Chile, France, Germany, Israel, Italy, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 2007
Enrollment StartMar 2008
Primary CompletionMar 2010
Study CompletionOct 2012
TodayJul 2026
First PostedNov 19, 2007
Enrollment StartMar 1, 2008
Primary CompletionMar 1, 2010
Study CompletionOct 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 18.6 years ago
Interventions
CP-751,871drug
Final dose 30 mg/kg IV on Day 1 of each 28 day cycle until either progression or toxicity